KAPA Company Profile and Key Details

KAPA has shown mixed momentum, losing -0.57% over the past week and -24.59% over the past quarter, though year-to-date performance is up 23.21%. Short-term trend indicators are bullishly aligned (SMA20 -9.42%, SMA50 -22.93%, SMA200 -38.59%). The stock’s 14-day RSI is 36.42 (weak momentum), while the ATR of 0.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -73.82% below its high and over 38.07% above its low. Average 10-day trading volume of 108.72 thousand shares is below the 3-month average of 264.10 thousand, indicating normal recent market interest.

Kairos Pharma, Ltd. has 23.70 million shares outstanding. The public float is 15.70 million shares, elevated short interest at 3.55% of float. This equals 517.82 thousand shares. The short ratio is 0.1 days. Institutional investors hold 11.05% of the float. Insiders own 37.2%. Yu John S holds 5.34 million shares, Murali Ramachandran has 133.06 thousand shares and Samuelson Doug has 60.80 thousand shares.

Kairos Pharma, Ltd. generated EPS of -$0.30 over the past year. Five-year average earnings growth is -23.37%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $9.00. The high target offers 435.71% upside. The low target suggests 435.71% downside. The mean target is $9.00. This offers 435.71% upside. Kairos Pharma, Ltd. earnings surprise history is a mixed track record. The quarter that ended August 12, 2026, missed forecasts by -33.33%. The prior quarter beat by 14.29%. Over the last six quarters, Apple has recorded several small beats. These include 33.33% in August 12, 2025.

Kairos Pharma, Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.71. This means the shares are trading near this model’s fair value.

Kairos Pharma, Ltd. trades at a P/E ratio of -0.86, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.22 suggesting the stock is closer to book value. The P/FCF stands at -1.29, also above market averages.

Kairos Pharma, Ltd. (AMEX:KAPA) closed at $1.68 USD, gaining $0.02 (1.20%) from the previous close of $1.66. The stock is currently mid-range between its 52-week high and low $1.51 and $13.02. With a market capitalization of about $5.14 million, Kairos Pharma, Ltd. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.48). Key stats such as the average daily volume over the past year has been around 332.45 thousand shares, volume is running light vs its 52-week average. Headquartered in Los Angeles, CA, Kairos Pharma, Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO John S. Yu, the company employs approximately 4 people and listed since September 16, 2024. Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer.

Kairos Pharma, Ltd. (AMEX:KAPA) shares are up 23.21% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Kairos Pharma, Ltd. trading at a premium to the broader market with a P/E of -0.86. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.88, suggesting 428.57% upside. Our AI forecast model points to short-term weakness (-13.1% over two weeks), a medium-term fall (-86.31% over three months), and a longer-term loss (-57.74% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Kairos Pharma, Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -13.1%, with price expected at $1.46 by September 24, 2026, within a range of $1.15 to $1.77 3-Month Outlook: Projected fall of -86.31%, reaching $0.23 by December 08, 2026, with a range of $0.00 to $0.56. 1-Year Outlook: Projected loss of -57.74%, with price at $0.71 by September 10, 2027, within a range of $0.00 to $0.00.